Literature DB >> 17102052

Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls.

Semin Chong1, Kyung Soo Lee, Ha Young Kim, Yoon Kyung Kim, Byung-Tae Kim, Myung Jin Chung, Chin A Yi, Ghee Young Kwon.   

Abstract

Integrated fluorine-18 fluorodeoxyglucose positron emission tomography (PET)-computed tomography (CT) for adrenal gland imaging in cancer patients allows early detection and accurate localization of adrenal lesions and differentiation of metastatic nodules from benign lesions, thereby facilitating treatment planning. However, false-positive findings are encountered at integrated PET-CT in approximately 5% of adrenal lesions identified as positive at PET, including adrenal adenomas, adrenal endothelial cysts, and inflammatory and infectious lesions. Moreover, false-negative findings may be seen in adrenal metastatic lesions with hemorrhage or necrosis, small-sized (<10-mm) metastatic nodules, and metastases from pulmonary bronchioloalveolar carcinoma or carcinoid tumors. An awareness of the potential pitfalls of integrated PET-CT enhances the diagnostic efficacy of this modality by allowing differentiation of metastatic adrenal lesions from other abnormalities. RSNA, 2006

Entities:  

Mesh:

Year:  2006        PMID: 17102052     DOI: 10.1148/rg.266065057

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  30 in total

1.  The use of positron emission tomography-computed tomography scan in the evaluation of a patient with Carney complex.

Authors:  Paul Byron Bandelin; Albert J Moreno; Homer Jess Lemar; Constantine A Stratakis; Thomas George Oliver
Journal:  J Clin Endocrinol Metab       Date:  2008-08       Impact factor: 5.958

Review 2.  Management of Adrenal Masses.

Authors:  Hattangadi Sanjay Bhat; Balagopal Nair Tiyadath
Journal:  Indian J Surg Oncol       Date:  2016-12-17

3.  FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Yoshihiko Fukukura; Yoriko Kajiya; Atushi Tani; Masayuki Nakajo; Yoshiaki Nakabeppu; Hiroshi Arimura; Yoshihiko Nishio; Fumihiko Nakamura; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2015-04-30       Impact factor: 5.315

Review 4.  Metachronous bilateral adrenal metastases following curative treatment for colorectal carcinoma.

Authors:  S G Thrumurthy; A M Jadav; M Pitt; M Dobson; A Hearn; N A Scott; S S Susnerwala
Journal:  Ann R Coll Surg Engl       Date:  2011-09       Impact factor: 1.891

5.  Benign hormone-secreting adenoma within a larger adrenocortical mass showing intensely increased activity on 18F-FDG PET/CT.

Authors:  Georgios Z Papadakis; Corina Millo; Constantine A Stratakis
Journal:  Endocrine       Date:  2016-05-06       Impact factor: 3.633

Review 6.  Metomidate-based imaging of adrenal masses.

Authors:  S Hahner; A Sundin
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 7.  Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature.

Authors:  Asha Kandathil; Ka Kit Wong; Daniel J Wale; Maria Chiara Zatelli; Anna Margherita Maffione; Milton D Gross; Domenico Rubello
Journal:  Endocrine       Date:  2014-10-02       Impact factor: 3.633

Review 8.  The indeterminate adrenal lesion.

Authors:  Anju Sahdev; Jon Willatt; Isaac R Francis; Rodney H Reznek
Journal:  Cancer Imaging       Date:  2010-03-18       Impact factor: 3.909

Review 9.  Differential diagnosis of adrenal mass using imaging modality: special emphasis on f-18 fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography.

Authors:  Hong Je Lee; Jaetae Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2014-03

Review 10.  The indeterminate adrenal mass in patients with cancer.

Authors:  A Sahdev; R H Reznek
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.